JP2018530530A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530530A5
JP2018530530A5 JP2018512125A JP2018512125A JP2018530530A5 JP 2018530530 A5 JP2018530530 A5 JP 2018530530A5 JP 2018512125 A JP2018512125 A JP 2018512125A JP 2018512125 A JP2018512125 A JP 2018512125A JP 2018530530 A5 JP2018530530 A5 JP 2018530530A5
Authority
JP
Japan
Prior art keywords
seq
combination according
group
deoxyribonucleic acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018512125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530530A (ja
Filing date
Publication date
Priority claimed from LU92821A external-priority patent/LU92821B1/en
Application filed filed Critical
Publication of JP2018530530A publication Critical patent/JP2018530530A/ja
Publication of JP2018530530A5 publication Critical patent/JP2018530530A5/ja
Pending legal-status Critical Current

Links

JP2018512125A 2015-09-09 2016-09-09 免疫刺激オリゴヌクレオチドを含む組合せ Pending JP2018530530A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU92821 2015-09-09
LU92821A LU92821B1 (en) 2015-09-09 2015-09-09 Combination comprising immunostimulatory oligonucleotides
PCT/EP2016/071314 WO2017042336A1 (en) 2015-09-09 2016-09-09 Combination comprising immunostimulatory oligonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020210230A Division JP2021059566A (ja) 2015-09-09 2020-12-18 免疫刺激オリゴヌクレオチドを含む組合せ

Publications (2)

Publication Number Publication Date
JP2018530530A JP2018530530A (ja) 2018-10-18
JP2018530530A5 true JP2018530530A5 (enExample) 2019-09-26

Family

ID=54251700

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018512125A Pending JP2018530530A (ja) 2015-09-09 2016-09-09 免疫刺激オリゴヌクレオチドを含む組合せ
JP2020210230A Pending JP2021059566A (ja) 2015-09-09 2020-12-18 免疫刺激オリゴヌクレオチドを含む組合せ
JP2022023832A Active JP7436535B2 (ja) 2015-09-09 2022-02-18 免疫刺激オリゴヌクレオチドを含む組合せ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020210230A Pending JP2021059566A (ja) 2015-09-09 2020-12-18 免疫刺激オリゴヌクレオチドを含む組合せ
JP2022023832A Active JP7436535B2 (ja) 2015-09-09 2022-02-18 免疫刺激オリゴヌクレオチドを含む組合せ

Country Status (17)

Country Link
US (3) US10487333B2 (enExample)
EP (1) EP3347468B1 (enExample)
JP (3) JP2018530530A (enExample)
KR (1) KR102411799B1 (enExample)
CN (1) CN108138179B (enExample)
AU (1) AU2016319214B2 (enExample)
CA (1) CA2997319C (enExample)
ES (1) ES2905891T3 (enExample)
IL (1) IL257921B (enExample)
LU (1) LU92821B1 (enExample)
MX (1) MX2018002665A (enExample)
PL (1) PL3347468T3 (enExample)
PT (1) PT3347468T (enExample)
RU (1) RU2766693C2 (enExample)
SI (1) SI3347468T1 (enExample)
WO (1) WO2017042336A1 (enExample)
ZA (1) ZA201801001B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
EP3392345A1 (en) 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
SG11202001709WA (en) * 2017-08-31 2020-03-30 Mologen Ag Tlr-9 agonists for modulation of tumor microenvironment
WO2019200238A1 (en) 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
US20200318200A1 (en) 2019-04-02 2020-10-08 The Brigham And Women's Hospital, Inc. Methods for Identifying Progression of a Primary Melanoma
CN112007149A (zh) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 一种新型复合免疫佐剂及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191115253A (en) 1911-06-30 1912-06-20 Adolph Schneider Improvements in Bottle-filling Machines.
US2382696A (en) 1939-04-01 1945-08-14 Milleville Marie Joseph Mau De Method and apparatus for filling containers
GB684057A (en) 1949-11-30 1952-12-10 Stockholms Bryggerier Ab Machine of the rotatory table type for the treatment of bottles and the like containers
US2699718A (en) 1952-04-10 1955-01-18 Francis X Wright Filling apparatus with beverage preparation mechanism
FR1418965A (fr) 1964-10-14 1965-11-26 Chelle Ets Tireuse de liquides à double utilisation
AU554222B2 (en) 1981-10-13 1986-08-14 Toyo Garasu K.K. Inspecting glass containers
ATE151076T1 (de) 1990-07-02 1997-04-15 Hoechst Ag Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-internucleotidverknüpfungen
JPH09502092A (ja) 1993-09-02 1997-03-04 リボザイム・ファーマシューティカルズ・インコーポレイテッド 非ヌクレオチドを含有する酵素性核酸
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
FR2732971B1 (fr) 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
CN1268140A (zh) 1996-10-16 2000-09-27 Icn药品公司 单环l-核苷、类似物及其应用
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6192481B1 (en) 1998-08-18 2001-02-20 International Business Machines Corporation Structure and method for power sequencing of disk drives in a computer system
ES2228454T3 (es) 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6737066B1 (en) 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
AU5821000A (en) 1999-06-29 2001-01-31 Smithkline Beecham Biologicals (Sa) Vaccine
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
AU1656601A (en) 1999-11-12 2001-06-12 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
WO2002060476A2 (de) 2001-01-31 2002-08-08 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Tumorvakzine
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
DK1432439T3 (da) 2001-10-02 2006-04-03 Mologen Ag Middel til forbedring af immunsvaret
AU2002349278A1 (en) 2001-10-02 2003-04-22 Mologen Ag Dna-expression construct for treatment of infections with leishmaniasis
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
JP2003204793A (ja) 2002-01-15 2003-07-22 Takeda Chem Ind Ltd ウイルス性疾患の予防または治療剤
DE10211558A1 (de) 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003287332A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7501503B2 (en) 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−aペプチドアナログ−ウイルス様粒子コンジュゲート
EP1631672B1 (de) 2003-06-10 2006-09-20 Mologen AG Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
SG122973A1 (en) 2003-10-30 2006-06-29 Coley Pharm Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
EP1691817A2 (en) 2003-12-02 2006-08-23 Corgentech, Inc. NF-kB OLIGONUCLEOTIDE DECOY MOLECULES
DK1699480T3 (da) 2003-12-30 2011-10-10 Mologen Ag Allogent terapeutisk tumormiddel
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2005116223A1 (de) 2004-05-28 2005-12-08 Mologen Ag Herstellungsverfahren geeigneter dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz
NZ552522A (en) 2004-06-15 2009-04-30 Idera Pharmaceuticals Inc Immunostimulatory oligonucleotide multimers
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
WO2006091591A1 (en) 2005-02-22 2006-08-31 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
US20060241076A1 (en) 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
JP2009511034A (ja) 2005-10-12 2009-03-19 キャンサー・リサーチ・テクノロジー・リミテッド 免疫異常を治療するための方法および組成物
EP2341059A1 (en) 2005-10-12 2011-07-06 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2007059041A2 (en) 2005-11-11 2007-05-24 Pfizer, Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
US7662949B2 (en) 2005-11-25 2010-02-16 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
BRPI0618907A2 (pt) 2005-11-25 2012-04-17 Mologen Ag c0nstructo de expressão de dna, método de produção de vetores, kit para produção de vetores e para produção de constructo de expressão
AU2007211334A1 (en) 2006-02-01 2007-08-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
CN101490257A (zh) * 2006-05-11 2009-07-22 莫洛根股份公司 用于免疫刺激的多聚体
AU2007260775A1 (en) 2006-06-13 2007-12-21 Bayhill Therapeutics, Inc. Methods and immune modulatory nucleic acid compositions for preventing and treating disease
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP3246409A1 (en) 2007-05-29 2017-11-22 Nature Technology Corporation Antibiotic-resistance-free vectors
KR101351195B1 (ko) 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
WO2009035554A2 (en) 2007-09-07 2009-03-19 University Of Florida Research Foundation, Inc. Superior structure stability and selectivity of hairpin nucleic acid probes with an l-dna stem
KR20100068422A (ko) 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
EP2058397A1 (de) 2007-11-07 2009-05-13 Mologen AG Multimeres Assemblat zur Immunstimulation
WO2009069447A1 (ja) 2007-11-28 2009-06-04 Toray Industries, Inc. インフルエンザワクチン用のアジュバント及びインフルエンザワクチン
JP5359883B2 (ja) 2007-11-28 2013-12-04 東レ株式会社 肝炎の治療剤又は予防剤
WO2010039137A1 (en) 2008-10-02 2010-04-08 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
EP2246433A1 (de) 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
GB201021873D0 (en) 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
JP5761707B2 (ja) 2011-02-02 2015-08-12 国立研究開発法人産業技術総合研究所 高効率細胞融合法
SG10201704992SA (en) * 2012-06-21 2017-07-28 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
EP3392345A1 (en) 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
SG11202001709WA (en) 2017-08-31 2020-03-30 Mologen Ag Tlr-9 agonists for modulation of tumor microenvironment

Similar Documents

Publication Publication Date Title
JP2018530530A5 (enExample)
RU2018108353A (ru) Комбинация, включающая иммуностимулирующие олигонуклеотиды
JP2014509511A5 (enExample)
JP2016116520A5 (enExample)
JP2013516190A5 (enExample)
HRP20241138T1 (hr) Oligonukleotidi za induciranje ekspresije očinskog ube3a
JP2019527563A5 (enExample)
JP2017505623A5 (enExample)
JP2018512041A5 (enExample)
JP2019506862A5 (enExample)
JP2018533954A5 (enExample)
JP2016513976A5 (enExample)
JP2015171368A5 (enExample)
JP2011509258A5 (enExample)
JP2016520310A5 (enExample)
JP2017536119A5 (enExample)
JP2012505657A5 (enExample)
JP2017070307A5 (enExample)
JP2016522674A5 (enExample)
JP2012505250A5 (enExample)
JP2014518612A5 (enExample)
JP2018519835A5 (enExample)
JP2013535210A5 (enExample)
JP2015532097A5 (enExample)
JP2015511821A5 (enExample)